Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1979 3
1981 2
1982 2
1983 2
1984 3
1985 5
1986 2
1988 1
1989 7
1990 7
1991 2
1992 3
1993 3
1994 3
1995 5
1996 3
1997 4
1998 8
1999 7
2000 13
2001 10
2002 15
2003 16
2004 11
2005 14
2006 12
2007 11
2008 9
2009 14
2010 13
2011 9
2012 7
2013 6
2014 10
2015 8
2016 19
2017 17
2018 18
2019 27
2020 19
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

323 results
Results by year
Filters applied: . Clear all
Page 1
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Eikelboom JW, et al. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844192 Free article. Clinical Trial.
Long-term use of ticagrelor in patients with prior myocardial infarction.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Bonaca MP, et al. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. N Engl J Med. 2015. PMID: 25773268 Free article. Clinical Trial.
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Criner GJ, et al. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112385 Clinical Trial.
Diastereomer-specific effects of double-stranded peptides conjugated with -L-Tyr-L-Phe- or -L-Tyr-D-Phe- residues on tyrosine phosphorylation and inhibition of src(ts)NRK, A431, MCF-7, and DU145 cell growth.
Kobayashi S, Atuchi N, Wakamatsu H, Hattori M, Kawada A, Asano K. Kobayashi S, et al. Chem Pharm Bull (Tokyo). 2007 Nov;55(11):1585-92. doi: 10.1248/cpb.55.1585. Chem Pharm Bull (Tokyo). 2007. PMID: 17978516 Free article.
Although the replacement of the L-Phe-L-Phe sequence with L-Tyr-L-Phe produces a less active inhibitor, the double-stranded peptide conjugated with L-Tyr-D-Phe is more active than that conjugated with L-Tyr-L-Phe. ...These data pro …
Although the replacement of the L-Phe-L-Phe sequence with L-Tyr-L-Phe produces a less active inhibitor, the doub …
Antiviral Activities of Hibiscus sabdariffa L. Tea Extract Against Human Influenza A Virus Rely Largely on Acidic pH but Partially on a Low-pH-Independent Mechanism.
Takeda Y, Okuyama Y, Nakano H, Yaoita Y, Machida K, Ogawa H, Imai K. Takeda Y, et al. Food Environ Virol. 2020 Mar;12(1):9-19. doi: 10.1007/s12560-019-09408-x. Epub 2019 Oct 16. Food Environ Virol. 2020. PMID: 31620998 Free PMC article.
Here, we analyzed the antiviral activity of hibiscus (Hibiscus sabdariffa L.) tea extract against human IAV and evaluated its potential as a novel anti-IAV drug and a safe inactivating agent for whole inactivated vaccine. ...
Here, we analyzed the antiviral activity of hibiscus (Hibiscus sabdariffa L.) tea extract against human IAV and evaluated its potenti …
Improved Intranasal Retentivity and Transnasal Absorption Enhancement by PEGylated Poly-l-ornithine.
Kamiya Y, Yamaki T, Omori S, Uchida M, Ohtake K, Kimura M, Yamazaki H, Natsume H. Kamiya Y, et al. Pharmaceuticals (Basel). 2018 Jan 25;11(1):9. doi: 10.3390/ph11010009. Pharmaceuticals (Basel). 2018. PMID: 29370117 Free PMC article.
We reported that the introduction of polyethylene glycol (PEG) to poly-l-ornithine (PLO), which is an homopolymeric basic amino acid having absorption-enhancement ability, prolonged retention time in an in vitro inclined plate test, probably due to an increase in viscosity …
We reported that the introduction of polyethylene glycol (PEG) to poly-l-ornithine (PLO), which is an homopolymeric basic amino acid …
Elucidation of anti-HIV mechanism of sulfated cellobiose-polylysine dendrimers.
Weiyue S, Ying L, Kanamoto T, Asai D, Takemura H, Nakashima H, Miyazaki K, Yoshida T. Weiyue S, et al. Carbohydr Res. 2020 Sep;495:108084. doi: 10.1016/j.carres.2020.108084. Epub 2020 Jun 24. Carbohydr Res. 2020. PMID: 32658833
The first, second, and third-generation derivatives exhibited potent anti-HIV activity with EC(50) values of 3.7, 0.6, and 1.5 mug/mL, respectively, in constant to sulfated oligosaccharides with low anti-HIV activity, while the second-generation sulfated dendrimer was the most ac …
The first, second, and third-generation derivatives exhibited potent anti-HIV activity with EC(50) values of 3.7, 0.6, and 1.5 mug/mL, respe …
Evolving population-based statistics for rare epithelial ovarian cancers.
Matsuo K, Machida H, Matsuzaki S, Grubbs BH, Klar M, Roman LD, Sood AK, Gershenson DM, Wright JD. Matsuo K, et al. Gynecol Oncol. 2020 Apr;157(1):3-11. doi: 10.1016/j.ygyno.2019.11.122. Epub 2020 Jan 15. Gynecol Oncol. 2020. PMID: 31954534 Free PMC article.
323 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page